DrugPatentWatch Database Preview
EPOGEN/PROCRIT Drug Profile
Email this page to a colleague
» See Plans and PricingSummary for Tradename: EPOGEN/PROCRIT
| Patents: | 95 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 2 |
| Recent Clinical Trials: | See clinical trials for EPOGEN/PROCRIT |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EPOGEN/PROCRIT |
Recent Clinical Trials for EPOGEN/PROCRIT
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Sandoz | Phase 3 |
Recent Litigation for EPOGEN/PROCRIT
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ameranth, Inc. v. Starbucks Corporation | 2013-05-06 |
Pharmacology for EPOGEN/PROCRIT
| Ingredient-type | Erythropoietin |
| Physiological Effect | Increased Erythroid Cell Production |
Company Disclosures: US Patents for EPOGEN/PROCRIT
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | EPOGEN/PROCRIT | epoetin alfa | VIAL; SINGLE-USE | 103234 | 001 | 1989-06-01 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2012-08-15 | RX | company | |
| Amgen | EPOGEN/PROCRIT | epoetin alfa | VIAL; SINGLE-USE | 103234 | 001 | 1989-06-01 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2013-08-20 | RX | company | |
| Amgen | EPOGEN/PROCRIT | epoetin alfa | VIAL; SINGLE-USE | 103234 | 001 | 1989-06-01 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for EPOGEN/PROCRIT
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | EPOGEN/PROCRIT | epoetin alfa | VIAL; SINGLE-USE | 103234 | 001 | 1989-06-01 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amgen | EPOGEN/PROCRIT | epoetin alfa | VIAL; SINGLE-USE | 103234 | 001 | 1989-06-01 | Start Trial | AMGEN INC. (Thousand Oaks, CA) | 2039-02-26 | RX | search | |
| Amgen | EPOGEN/PROCRIT | epoetin alfa | VIAL; SINGLE-USE | 103234 | 001 | 1989-06-01 | Start Trial | 2036-04-01 | RX | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for EPOGEN/PROCRIT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010282361 | Start Trial |
| Canada | 2676551 | Start Trial |
| Canada | 2733911 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
